Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Proves Resilient In 2020 Despite Some Bumpy Launches

Rivals To Advair And Vascepa Suffer From Delays And API Scarcity

Executive Summary

Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.

You may also be interested in...



Ups And Downs See Mid-Table Players Shift Position

Mid-table players jostle for position as we continue to work our way through Generics Bulletin’s annual Top 50, with mixed fortunes over the past year seeing some companies rise up the rankings as others decline.

Hikma Is Taking Another Look At US Biosimilars

Hikma CEO Siggi Olafsson has outlined the potential future opportunity that the firm sees in the US biosimilars market, in the second part of an exclusive interview with Generics Bulletin.

Hikma’s Olafsson Offers Latest On Advair And Vascepa Rivals

Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel